Recently, the list of corporate headquarters enterprises in Sichuan Province for 2025 was announced, with 31 enterprises across the province being recognized as corporate headquarters enterprises. Among them, 20 were designated as all-around corporate headquarters enterprises, five as functional headquarters enterprises, and six as growth-oriented headquarters enterprises. Biokin Pharmaceutical was recognized as an "all-around corporate headquarters enterprise."
Headquarter companies refer to corporate enterprises registered in Sichuan that fulfill functions such as tax payment, statistical reporting, and settlement. They operate across provinces through investment or authorized management, have reached a relatively large scale of development, undertake headquarters functions, exert industry influence, and make fiscal and tax contributions. Based on the scale of development, actual control rights, and functions undertaken by the enterprise or its branches, Sichuan classifies headquarters companies into three categories: all-round headquarters, functional headquarters, and growth-oriented headquarters. The identification of headquarters companies is organized by relevant provincial departments, including the Sichuan Provincial Development and Reform Commission, the Department of Economy and Information Technology, the Department of Science and Technology, the Administration for Market Regulation, and the Economic Cooperation Bureau.
A comprehensive headquarters enterprise requires its operating revenue, total assets, number of employees, and other indicators to meet the criteria for large-scale enterprises. In recent years, Biokin Pharmaceutical has deeply engaged in the pharmaceutical and health sector, adhered to independent innovation, and focused on cutting-edge directions in cancer treatment, investing substantial resources in the research and development of ADC drugs. Several innovative drugs targeting high-quality ADC targets, such as iza-bren (BL-B01D1) and T-Bren (BL-M07D1), are currently in clinical research stages, with over 90 clinical trials being conducted globally. In 2025, the first antibody-radionuclide conjugate (ARC) drug, BL-ARC001, received clinical trial approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration, while the independently developed HER2 antibody-drug conjugate (ADC) T-Bren (BL-M07D1) was included in CDE’s breakthrough therapy designation list. An overseas licensing deal triggered a milestone payment of $250 million, the largest single milestone payment for a domestic ADC asset to date. Additionally, the company was selected among the "2025 China’s 50 Most Innovative Companies," with its market capitalization exceeding 150 billion yuan.
In the future, leveraging the support provided by Sichuan Province for headquarters enterprises, Biokin Pharmaceutical will continue to focus on the global frontiers of the biopharmaceutical industry. Rooted in addressing unmet clinical needs, the company will maintain globally leading capabilities in innovative R&D, global clinical development, and large-scale production and supply within the field of macromolecular tumor therapy (ADC/GNC/ARC). By deepening its global innovation layout and further amplifying the cluster effect and driving influence of a headquarters enterprise, Biokin Pharmaceutical will inject new momentum into the high-quality development of Sichuan’s biopharmaceutical industry.
